The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia
Open accessAbstract
BACKGROUND: Hypophosphatasia results from mutations in the gene for the tissue-nonspecific isozyme of alkaline phosphatase (TNSALP). Inorganic pyrophosphate accumulates extracellularly, leading to rickets or osteomalacia. Severely affected babies often die from respiratory insufficiency due to progressive chest deformity or have persistent bone disease. There is no approved medical therapy. ENB-0040 is a bone-targeted, recombinant human TNSALP that prevents the manifestations of hypophosphatasia in Tnsalp knockout mice. METHODS: We enrolled infants and young children with life-threatening or debilitating perinatal or infantile hypophosphatasia in a multinational, open-label study of treatment with ENB-0040. The primary objective was the healing of rickets, as assessed by means of radiographic scales. Motor and cognitive development, respiratory function, and safety were evaluated, as well as the pharmacokinetics and pharmacodynamics of ENB-0040. RESULTS: Of the 11 patients recruited, 10 completed 6 months of therapy; 9 completed 1 year. Healing of rickets at 6 months in 9 patients was accompanied by improvement in developmental milestones and pulmonary function. Elevated plasma levels of the TNSALP substrates inorganic pyrophosphate and pyridoxal 5'-phosphate diminished. Increases in serum parathyroid hormone accompanied skeletal healing, often necessitating dietary calcium supplementation. There was no evidence of hypocalcemia, ectopic calcification, or definite drug-related serious adverse events. Low titers of anti-ENB-0040 antibodies developed in four patients, with no evident clinical, biochemical, or autoimmune abnormalities at 48 weeks of treatment. CONCLUSIONS: ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
Mammalian Alkaline Phosphatases: From Biology to Applications in Medicine and Biotechnology
Millán, J. L. (2006) · doi:10.1002/3527608060 · Cited by 421
Self-citation
Cited by
Hypophosphatasia — aetiology, nosology, pathogenesis, diagnosis and treatment
Whyte, M. P. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.14 · Cited by 511
Self-citationAlkaline Phosphatase and Hypophosphatasia
Millán, J. L., & Whyte, M. P. (2016) · Calcified Tissue International · doi:10.1007/s00223-015-0079-1 · Cited by 397
Self-citationAlkaline phosphatase: a novel treatment target for cardiovascular disease in CKD
Haarhaus, M., Brandenburg, V., Kalantar-Zadeh, K., Stenvinkel, P., & Magnusson, P. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.60 · Cited by 316
Sato, M., Saitoh, I., Kiyokawa, Y., Iwase, Y., Kubota, N., Ibano, N., Noguchi, H., Yamasaki, Y., & Inada, E. (2021) · Cells · doi:10.3390/cells10123338 · Cited by 29
Dental outcomes for children receiving asfotase alfa for hypophosphatasia
Schroth, R. J., Long, C., Lee, V. H. K., Alai-Towfigh, H., & Rockman-Greenberg, C. (2021) · Bone · doi:10.1016/j.bone.2021.116089 · Cited by 29
Metadata
- Authors
- Whyte, M. P., Greenberg, C. R., Salman, N. J., Bober, M. B., McAlister, W. H., Wenkert, D., Van Sickle, B. J., Simmons, J. H., Edgar, T. S., Bauer, M. L., Hamdan, M. A., Bishop, N., Lutz, R. E., McGinn, M., Craig, S., Moore, J. N., Taylor, J. W., Cleveland, R. H., Cranley, W. R., Lim, R., Thacher, T. D., Mayhew, J. E., Downs, M., Millán, J. L., Skrinar, A. M., Crine, P., & Landy, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-08
- Volume
- 366
- Issue
- 10
- Pages
- 904-913
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141225628
- Cited by
- 568
- References
- 2
- FWCI
- 28.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. https://app.cochat.ai/papers/10.1056/nejmoa1106173
- The paper
- Whyte, M. P., Greenberg, C. R., Salman, N. J., Bober, M. B., McAlister, W. H., Wenkert, D., Van Sickle, B. J., Simmons, J. H., Edgar, T. S., Bauer, M. L., Hamdan, M. A., Bishop, N., Lutz, R. E., McGinn, M., Craig, S., Moore, J. N., Taylor, J. W., Cleveland, R. H., Cranley, W. R., . . . Landy, H. (2012). Enzyme-Replacement Therapy in Life-Threatening Hypophosphatasia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1106173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.